(Q32133943)

6 July 2017

1 reference

title

The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety (English)

1 reference

6 July 2017

1 reference

1

Przedborski S

1 reference

6 July 2017

Vernice Jackson-Lewis

2

object named as

Jackson-Lewis V

1 reference

6 July 2017

Naini AB

3

1 reference

6 July 2017

Jakowec M

4

1 reference

6 July 2017

Petzinger G

5

1 reference

6 July 2017

Miller R

6

1 reference

6 July 2017

Akram M

7

1 reference

6 July 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

Journal of Neurochemistry

6 July 2017

1 reference

6 July 2017

76

1 reference

6 July 2017

1265-1274

1 reference

6 July 2017

5

1 reference

Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

6 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Chronic parkinsonism secondary to intravenous injection of meperidine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

1-Methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

MPTP toxicity: implications for research in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

The Impact of Gender and Estrogen on Striatal Dopaminergic Neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Selegiline can mediate neuronal rescue rather than neuronal protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1471-4159.2001.00183.X

10.1046/J.1471-4159.2001.00183.X

21 January 2018

Identifiers

DOI

1 reference

6 July 2017

1 reference